ELCC 2023 - European Lung Cancer Congress 2023
Mar 29 - Apr 01, 2023 | CopenhagenDenmark
LARVOL is not affiliated with European Lung Cancer Congress 2023 and all trademarks, logos, and brand names are property of their respective owners
Showing 67 abstracts linked to Trials
Updated survival, efficacy and safety of adjuvant (adj) atezolizumab (atezo) after neoadjuvant (neoadj) atezo in the phase II LCMC3 study
Discussion
Mini Oral 1Updated Efficacy and Safety of Taletrectinib in Patients (pts) with ROS1+ Non-Small Cell Lung Cancer (NSCLC)
Discussion
Mini Oral 2First-line cemiplimab for locally advanced non-small cell lung cancer: Updated subgroup analyses from EMPOWER-Lung 1 and EMPOWER-Lung 3
Discussion
Mini Oral 2Safety and efficacy of tusamitamab ravtansine in combination with pembrolizumab ± chemotherapy in patients with CEACAM5-positive nonsquamous NSCLC (CARMEN-LC05 phase 2 study)
Discussion
Mini Oral 2EMPOWER-Lung 1: Cemiplimab (CEMI) monotherapy as first-line (1L) treatment of patients (pts) with brain metastases from advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) _50%: 3-year update
Discussion
Mini Oral 2Patterns of response in metastatic (m) NSCLC after 2 and 4 cycles of chemotherapy (CT), alone or with durvalumab (D) ± tremelimumab (T), in the phase 3 POSEIDON study
Discussion
Mini Oral 2Final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3) & pembrolizumab in 2nd line metastatic NSCLC pts resistant to PD-1/PD-L1 inhibitors
Discussion
Mini Oral 2Sotorasib in KRAS G12C-mutated advanced non-small cell lung cancer (aNSCLC): overall survival (OS) data from the global expanded access program (EAP study-436)
Discussion
Mini Oral 1Adagrasib (MRTX849) in Patients With Advanced/Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer (NSCLC): Preliminary Analysis of Mutation Allele Frequency
Discussion
Mini Oral 1Efficacy and ctDNA analysis in an updated cohort of patients with TRK fusion lung cancer treated with larotrectinib
Discussion
Mini Oral 2Clinical impact of plasma EGFR analysis: results from the ETOP-BOOSTER randomized phase II trial
Discussion
Mini Oral 2Neoadjuvant nivolumab (N) + platinum-doublet chemotherapy (C) for resectable NSCLC: 3-y update from CheckMate 816
Osimertinib versus gefitinib followed by osimertinib in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE trial
CONTACT-01: Efficacy and safety from a Ph 3 study of atezolizumab (atezo) + cabozantinib (cabo) vs docetaxel (doc) monotherapy in patients (pts) with metastatic NSCLC (mNSCLC) previously treated with checkpoint inhibitors and chemotherapy
Long-term efficacy, safety, and predictors of response to amivantamab among patients with post-platinum EGFR Ex20ins-mutated advanced NSCLC